TY - JOUR
T1 - In vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3 -dioxolane]platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines
AU - Hong, W. S.
AU - Kim, H. T.
AU - Kim, K. H.
AU - Kim, D. K.
PY - 1995
Y1 - 1995
N2 - The in vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) (SKI 2053R, NSC D644591), cisplatin (CDDP) and carboplatin (CBDCA) was determined against two human lung cancer (PC-9 and PC-14) and two human stomach cancer (MKN-45 and KATO III) cell lines by human tumor clonogenic assay. The activity of SKI 2053R was compared with those of CDDP and CBDCA in terms of relative antitumor activity (RAA, peak plasma concentration/IC50). Mean IC50 values (μg/ml) of SKI 2053R, CDDP and CBDCA were 6.4 ± 0.8, 1.8 ± 0.7 and 20.6 ± 12.2, respectively. The RAAs of SKI 2053R, CDDP and CBDCA were 1.6 ± 0.4, 2.0 ± 0.8 and 1.2 ± 0.6, respectively. The differences in these values were not statistically significant. The results, demonstrating that antitumor activity, of SKI 2053R is similar to those of CDDP and CBDCA, suggest that SKI 2053R is an interesting candidate for further development as a new anticancer drug.
AB - The in vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) (SKI 2053R, NSC D644591), cisplatin (CDDP) and carboplatin (CBDCA) was determined against two human lung cancer (PC-9 and PC-14) and two human stomach cancer (MKN-45 and KATO III) cell lines by human tumor clonogenic assay. The activity of SKI 2053R was compared with those of CDDP and CBDCA in terms of relative antitumor activity (RAA, peak plasma concentration/IC50). Mean IC50 values (μg/ml) of SKI 2053R, CDDP and CBDCA were 6.4 ± 0.8, 1.8 ± 0.7 and 20.6 ± 12.2, respectively. The RAAs of SKI 2053R, CDDP and CBDCA were 1.6 ± 0.4, 2.0 ± 0.8 and 1.2 ± 0.6, respectively. The differences in these values were not statistically significant. The results, demonstrating that antitumor activity, of SKI 2053R is similar to those of CDDP and CBDCA, suggest that SKI 2053R is an interesting candidate for further development as a new anticancer drug.
KW - Human lung and stomach cancer cell lines
KW - Human tumor clonogenic assay
KW - New platinum complex (SKI 2053R)
UR - http://www.scopus.com/inward/record.url?scp=0029004753&partnerID=8YFLogxK
M3 - Article
C2 - 7733640
AN - SCOPUS:0029004753
SN - 0250-7005
VL - 15
SP - 51
EP - 54
JO - Anticancer Research
JF - Anticancer Research
IS - 1
ER -